This Viewpoint discusses a New York law that allows the state to negotiate rebates with manufacturers to obtain value-based prices for drugs in its Medicaid program and assesses the potential effects of value-based pricing.
This Viewpoint explores why biosimilars for chronic diseases, the largest category of biological therapies, are unlikely to yield cost savings.
This pragmatic randomized trial compares the effects of a second anti–tumor necrosis factor (TNF) drug vs non–TNF-targeted biologic therapy among patients with rheumatoid arthritis for whom a first anti-TNF drug had failed.
This narrative review summarizes current evidence about the diagnosis and treatment of polymyalgia rheumatica and giant cell arteritis.
You currently have no searches saved.